spacer
Leftshadow
Point-of-care (POC) diagnostic tests and technology for the detection of infectious diseases developed, manufactured and licensed by Chembio Diagnostic Systems, Inc.
 
 

Welcome
Chembio Diagnostic Systems, Inc. (Chembio) (OTCQB: CEMI) develops, manufactures, licenses and markets point-of-care (POC) diagnostic tests and technology for the detection of infectious diseases. Founded in 1985, Chembio entered the POC testing field in the late 1990's and, in 2002, focused its business to participate in the emerging global need and opportunity for rapid HIV tests. Today the company is a leading employer on Long Island, with approximately 170 employees.   Revenues during the 2nd half of 2011 were nearly $12MM, an annualized rate of $24MM.  The company has been profitable since 2009 and anticipates continued revenue growth and profitability in 2012.

Chembio's Dual Path Platform (DPP®) POC technology was awarded United States Patent No. 7,189,522 in March 2007. DPP® enables development of POC assays that provide unique features and capabilities such as multiplexing and improved control of challenging sample types, such as oral fluid. An HIV oral fluid test is anticipated to be submitted to and reviewed by the FDA in 2012.  Several other tests have also been developed on DPP® and revenues in this product line are expected to grow significantly in 2012. The company is uniquely positioned to participate in the emerging U.S. market with this and other rapid HIV tests that are already FDA approved for use in professional (i.e.  public health and emergency room) settings. 

more... company profile (pdf download)

The Dual Path Platform (DPP®) Technology

Chembio’s Patented Point-of-Care Testing Platform

Dual Path Platform
(DPP®)

The Dual Path Platform (DPP®) Technology (US Patent# 7,189,522) was developed as a platform for next generation, rapid diagnostic testing. Chembio believes that this technology allows the freedom to operate in the POC sector and offers a novel, low-cost, rapid technology as an attractive alternative to established point of care formats including lateral flow. Advantages of DPP include increased analytical and clinical sensitivity, multiplexing capabilities and quantifiable results. The technology is available for application in diverse global diagnostic markets for human and veterinary assays, food safety, bioterrorism, environmental testing, etc.

Description: Rapid Tests for Earlier Treatment of HIV, Syphilis, Hepatitis and TB, using Chembio's Patented Dual Path Platform Technology

DPP Features:

    • Increased analytical and clinical sensitivity
    • Outside the standard lateral flow IP
    • Less labor intensive than EIA, PCR or WB
    • Potential ideal confirmatory test
    • Adaptable to multiple sample types: blood serum, oral fluid, sputum urine, feces, etc.
    • Multiplex capability through elimination of
      aggregation issues (ie HIV/TB, HIV 1/ 2, etc.)
    • Ideally suited for POC testing
    • Requires minimal sample volume
    • Long shelf life (up to 24 months)
    • Total test time < 20 minutes

Diverse Potential Applications include:

spacer
News
   

New Chembio Syphilis Product Presented at the 18th Society for Sexually Transmitted Disease Research (ISSTDR) Congress in London, England.

Click to view Poster

   
 -PRESS RELEASES -
Date: Title:
   
05/08/2012 Chembio Diagnostics Reports First Quarter 2012 Financial Results
   
04/30/2012

Chembio to Present at Taglich Brothers Small Cap Equity Conference Tomorrow

   
04/24/2012

Chembio to Host Conference Call to Discuss 1st Quarter 2012 Financial Results

   
04/18/2012

Chembio Reports Completion of Enrollment in Pivotal Trial for DPP® Point-of-Care HIV 1/2 Test

   
03/08/2012

Chembio Diagnostics Reports Fourth Quarter and 2011 Financial Results

   
02/23/2012

Chembio to Host Conference Call to Discuss 2011 Financial Results

   
01/09/2012

Chembio Presenting at Biotech Conference

   
01/03/2012 Chembio Provides Business Update
   
   
   
   
  Press Releases

 
Events Calendar spacer
 
Date: Title:
   
05/08/2012

Chembio to Host Conference Call to Discuss 1st Quarter 2012 Financial Results

   
06/16 - 06/19/2012

American Society for Microbiology

ASM San Francisco, CA

   
06/18 - 06/21/2012

Bio International Conference

Boston Convention & Exhibition

Center, Boston, MA

   
06/27 - 06/29/2012

BASHH 2012 Spring Meeting

Jointly held with the ASTDA

Brighton Dome, UK

   
07/15 - 07/19/2012

American Association for Clinical

Chemistry AACC Annual Meeting

Los Angeles, CA  Booth 2351

   
11/14 - 11/17/2012

MEDICA- Dusseldorf Trade Centre,

Messeplatz, Dusseldorf, Germany

   
12/11 - 12/14/2012

APHL- Association of Public Health

Laboratories HIV Testing Conference

Altanta, GA

   
01/28 - 01/31/2013

Arab Health Exhibition & Conference

Dubai International Convention &

Exhibition Centre, Dubai

   
  Events & Tradeshows
     
spacer
 
spacer
About Us read more
Leftshadow
shadow shadow shadow
   
 
     
About Events Investor Section read more About Chembio Download Company Profile